

SUPPORTING INFORMATION

A Zr-based metal-organic framework drug release system with long-lasting antibacterial behavior for accelerating wound healing

Hui-Qian Zheng,^a Han-Xiao Feng,^a Bing-Xin Li,^a Yi-Fei Hui,^a Yi-Han Lin,^a Xian-Feng Su,^a Lai-Peng Yan,^{*b,c,d} Zijie Zhou,^{b,c,d} Zu-Jin Lin,^{*a} and Faqiang Tang^{*b,c,d}

^a Department of Applied Chemistry, College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, P. R. China.

^b Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, P. R. China. E-mail: yanlaipeng@fjmu.edu.cn; faqiangtang@fjmu.edu.cn.

^c Orthopedic and Sports Medicine Center, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, P. R. China.

^d Orthopedic and Sports Medicine Center, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, 350001, P. R. China.

*Author to whom correspondence can be addressed: yanlaipeng@fjmu.edu.cn, faqiangtang@fjmu.edu.cn, and linzujin@fafu.edu.cn.




Fig. S1 Pore distribution of SU-102 and CIP@SU-102 derived from N₂ sorption isotherms by DFT model.




Fig. S2 Particle size distributions of (a) SU-102 and (b) CIP@SU-102.




Fig. S3 Zeta potential of SU-102 and CIP@SU-102.




Fig. S4 Inhibition zone experiments of SU-102, CIP@SU-102 and CIP against *E. coli*, *S. aureus* and MRSA, respectively.




Fig. S5 Plate photographs showing the antimicrobial performances of CIP@SU-102 after 20 days' CIP release.




Fig. S6 SEM images of bacteria before and after treating with CIP@SU-102.




Fig. S7 Fluorescence images (AO/PI images) of live/dead (green/red) bacteria under various treatments.

Table S1 MBC values of as-prepared CIP@SU-102 against *E. coli*, *S. aureus*, and MRSA, respectively.

	CIP@SU-102	CIP@SU-102 after drug release		
		PBS, pH=7.4	PBS, pH=5.0	H ₂ O
<i>E. coli</i>	0.5	2.0	8.0	1.0
<i>S. aureus</i>	8.0	16	16	16
MRSA	32	64	32	32